© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Niclofolan owes its origins to the surge of organofluorine chemistry in the late twentieth century, riding high on a global wave of antiparasitic breakthroughs. Researchers in the 1970s set their sights on halogen-rich molecules, hoping to outsmart tapeworms and other stubborn parasites. As it turned out, Niclofolan packed enough punch to disrupt the playbook for animal health, spurring intense animal trials throughout Europe and Asia. Early studies underlined its potential as a veterinary tapeworm drug, but red flags over toxicity and lingering residues kept regulatory agencies on edge. While many labs welcomed its power, hesitation hung in the air, and some governments decided not to hand out rubber stamps for widespread use, pushing manufacturers and scientists to take a closer look at the trade-off between potency and safety.
This compound shows up as an organofluorine-based anthelmintic agent targeting tapeworms in veterinary practice. The crystalline material tends to show off a white to light-yellow hue, sometimes delivering a faint chemical odor. The active ingredient earns attention in cattle and poultry farming, and its handling protocol leans on careful dosing, often set apart from broad-spectrum antiparasitics. At the commercial level, pharmaceutical suppliers deal with Niclofolan in bulk powders, carefully packaged to shield it from humidity and accidental spills. Any farmhand who has ever prepped a worming program understands how much hinges on precision when bringing this tool out of the cabinet.
Niclofolan, at room temperature, sits as a crystalline powder with a melting point hovering between 215°C and 220°C. It resists breakdown under mild heat but doesn’t enjoy moisture or strong sunlight, both of which stir decomposition. The compound brands itself with significant fluorination—this grants it both fat-solubility and persistent chemical stability. Some lab tests recorded low aqueous solubility (often below 20 mg/L), nudging formulators to develop suspension-based delivery systems. The odor doesn’t scream for attention, but lingering chemical notes still turn up during handling. Its robust molecular weight, always a pain for tissue clearance, has driven much of the back-and-forth between efficacy and food safety.
Niclofolan products usually come with clear-cut labels, sharing batch numbers, active content (nearly always above 98% purity), and proper instructions for dissolution. Many suppliers use amber glass or reinforced high-density plastics for prolonged storage. Detailed leaflets follow most shipments, laying out the expiry, registration number, dosage for target species, and the mandated withdrawal period for edible tissues. Most manufacturers stamp each container with hazard warnings, covering skin, eye, and inhalation exposure. For international sales, UN classification and appropriate shipping codes help keep things above board.
Lab-scale synthesis typically begins with multi-stage fluorination of an aromatic precursor, followed by chlorination steps and careful temperature control to prevent runaway side reactions. The process frequently employs anhydrous hydrogen fluoride, not the friendliest of reagents, and requires skilled specialists to manage toxic fumes. After halogenation, the intermediate gets worked up with specific organophosphorus agents to create the bis(2-chloroethyl) phosphate side chain distinctive to Niclofolan. Final steps include solvent extraction, crystallization, and vacuum drying, all tailored to match purity specifications demanded in animal drugs.
Niclofolan stands up to many common acids and bases, but extended contact with strong reductants or high-powered oxidizers can split the molecule, generating both toxic and environmentally persistent byproducts. Chemists have tinkered with side groups, hoping to lower tissue retention or introduce alternative functional groups for wider activity. Still, minor changes often drop the entire antiparasitic activity. The phosphate moiety, stubborn as a mule, resists direct hydrolysis but cracks under extreme pH during forced degradation studies, letting laboratories predict shelf-life and possible drug-drug interactions.
While many know the compound as Niclofolan, it crops up under alternative monikers like Nicodifolan, R 29011, and 2,2-Dichloro-N-[bis(2-chloroethyl)amino]-1,1,1-trifluoroethane-1-phosphoric acid. In veterinary circles, some pharma labels use trade names to sidestep chemical tongue-twisters. That doesn’t hide the strict labeling rules, which always demand prominent display of the chemical identity for import, export, and regulatory compliance. Unspoken lingo among veterinarians leaves out unnecessary fluff—everyone calls it what they need to, as long as instructions remain clear at the farm gate.
Niclofolan draws respect in the handling department, thanks to toxicity warnings that show up on burnished safety sheets and regulatory manuals. Direct contact with skin begs for gloves, while any hint of dust in the air justifies a properly fitted respirator. Storage stresses dry, well-ventilated rooms, away from both animal feed and acids or oxidizers. Emergency spill kits, plenty of adsorption powders, and eye-wash stations earn their keep in labs and storerooms handling the chemical. The real seasoning comes from workers who echo the same motto: treat unknowns as dangerous until proven otherwise. Training never takes a back seat—even experienced operators go through the same playbook from time to time.
Niclofolan carved itself a spot in the veterinary antiparasitic sector, where the battle with tapeworms in livestock calls for serious chemistry. Farmers in regions fighting high tapeworm prevalence embraced the drug, counting on it to reduce infestations and push up yields. Poultry and cattle top the recipient list. Compliance with strict meat and milk residue laws keeps every user on high alert—inspectors hold detailed records, and food safety authorities don’t hesitate to visit. Outside farming, medical researchers keep an eye on its structure, hunting for ideas that might jump-start new generations of antiparasitics. Environmental regulators study its breakdown in feedlots, seeking to limit persistence and contamination in soil and groundwater.
R&D in the Niclofolan arena thrashed between dreams of complete tapeworm eradication and nightmares about toxicity. Many labs built studies linking structure to potency, drawing lessons on how minor tweaks can ruin efficacy or tip the safety balance the wrong way. Investigators dug deep into tissue distribution, documenting slow elimination and flagging concerns about meat safety. More recently, new tools such as high-resolution mass spectrometry make it easier to track trace residues or catch breakdown products before they build up. New formulations and delivery systems try to keep doses effective while limiting off-target exposure, hoping technology can outpace regulatory worries. Collaboration between universities, regulators, and industry still charts the map forward, but few underestimate the hurdles left to clear.
Toxicity drew early headlines in the Niclofolan story. Animal models showed acute toxicity at surprisingly low dosages, hitting the nervous system and the liver hardest. Further down the chain, tissue residue studies found sluggish clearance, especially in fatty tissues—a red flag for any compound destined for food-producing animals. Several countries never approved the compound for food animals, and others imposed strict withdrawal periods. Guidelines stress regular blood work, watching for signs of toxicity before animals move through slaughterhouses. Studies on environmental fate point to long-term persistence if spills or manure contamination escape cleanup, leading many farm managers to stick with closed-loop disposal and best-practice handling protocols.
Niclofolan stands at a crossroads, facing stiffer regulatory reviews and new antiparasitic challengers with better safety records. While some markets still value its knockout power, pressure grows to phase out drugs linked to residue scares and resistance. Chemists keep tinkering, blending old-school organofluorine power with new targeting strategies, enzyme triggers, or biodegradable carriers. Veterinary medicine, always hungry for reliable tapeworm control, leans on robust research and honest risk analysis. Regulatory agencies want transparent studies, plain-spoken safety data, and strict compliance at every step. Whether or not Niclofolan hangs on for the long haul, its story reminds every researcher and farmer that chemical tools demand both respect and responsibility.
Niclofolan doesn't crop up in casual conversations unless you follow pharmaceutical news or medical research. Researchers have studied it mostly as an antiparasitic drug. This means it fights off certain types of worms and parasites that can get into people or animals, often through contaminated water or poor hygiene conditions.
In the last twenty years, more attention has turned toward health problems caused by parasites. Poor sanitation and lack of clean water in some countries let these infections spread quickly. According to the World Health Organization, more than one billion people suffer from soil-transmitted helminth infections. Medicines like niclofolan can make a huge difference for them.
Doctors have looked at niclofolan as a possible treatment for tapeworms, threadworms, and a few other tough-to-treat worms. Some of these infections cause constant fatigue, digestive trouble, or worse. The right medicine means people can go back to school, work, or raising their families without missing days or weeks from illness.
Not every drug that works in the lab proves safe enough for everyone. Concerns around niclofolan have surfaced because some studies showed possible side effects in animals, including changes in the liver. Regulators in North America, Europe, and parts of Asia keep a close eye out for medicines with toxic side effects because those risks can outweigh the benefits. In some places, niclofolan never entered clinical use or received approval, even if other countries kept it as a backup option for severe cases.
People dealing with parasite infections sometimes have few choices, though. So doctors weigh the evidence. If a patient faces a dangerous tapeworm infection that doesn’t respond to safer treatments, using a drug like niclofolan might make sense. Proper monitoring can catch problems early.
I remember that in my college pharmacology classes, we always spent extra time on drugs considered “second-line” or “reserve”—medicines kept aside for when regular options fail. Niclofolan fell into that group. The debate usually focused on weighing risks against benefits, along with social issues like drug access in low-income regions.
There’s a broader point here. Drug development needs real-world testing, not just computer models and early lab data. The experience of patients, the watchful eye of healthcare workers, and the follow-up of researchers all matter. Niclofolan’s track record shows how a promising drug must stay under the microscope, especially when it’s not widely used.
For people suffering with parasite infections in the developing world, having more drug options matters. The big step involves improving regulatory oversight. Governments, drug companies, and global health organizations should team up to strengthen surveillance for side effects and share data quickly. Rolling out better education about safe drug use to doctors and communities closes the information gap.
Efforts should continue to develop new medicines that combine the effectiveness of drugs like niclofolan without causing harm. Programs focused on clean water, sanitation, and routine parasite screening remain just as important. Medicines handle infections as they come—but prevention and responsible surveillance block outbreaks before they begin.
Niclofolan holds a place in the world of pharmaceuticals as an old-school anti-parasitic drug. People might remember it under trade names like Ripercol, once used to treat tapeworm infections in animals and sometimes in people. Modern veterinarians rarely reach for it because newer, safer treatments showed up over the years.
My medical studies dragged up cases where Niclofolan still got a mention in rural clinics, especially in regions lacking access to newer tapeworm drugs like praziquantel. The draw: Niclofolan gets rid of several species of tapeworm. Yet, across journal articles and pharmacology texts, the warnings appear just as often as the benefits.
People who took Niclofolan for tapeworm often reported stomach aches, diarrhea, nausea, and cramps. Some described a sense of dizziness and headache after a dose or two. I remember a parasitology professor sharing old patient case records where folks just felt “out of sorts” for a couple of days — a catch-all description for fatigue, mild confusion, or a foggy feeling.
Reports surfaced over the years of liver issues after Niclofolan use. Lab results sometimes showed raised liver enzymes, a red flag for doctors. Signs like jaundice or dark urine acted as warning bells that the drug stressed the liver. My own mentor warned that pre-existing liver disease made Niclofolan risky even at lower doses. Toxicity builds up quietly, so a simple treatment for worms sometimes led to a bigger medical problem.
Some rare cases: people broke out in rashes, hives, or swelling after taking Niclofolan. These allergic reactions needed swift action with antihistamines or even a hospital visit. With any chemical compound, there’s always the chance someone’s immune system will overreact.
Bloodwork on treated patients turned up anemias and shifts in white cell count. A handful of cases revealed peripheral nerve symptoms: tingling, numbness, sometimes muscle weakness. Not everyone gets these symptoms, but doctors watch closely, especially in kids or people with weak immune systems.
Each side effect tells a story about who should avoid Niclofolan. Long-term users, folks with liver troubles, and those who react badly to other anti-parasitics all need extra attention. Today, drug monitoring is better than in the 1960s or ’70s, which means catching trouble before it grows.
Pharmaceutical advances brought us drugs like praziquantel, which clear tapeworms quickly with fewer complaints of nausea or liver strain. Most prescribers dropped Niclofolan for a reason. Still, in corners of the world where it’s all that’s available, education and monitoring can soften the risk. Doctors weigh out benefits and harms with a heavy dose of past experience and a sharp eye on the latest case reports.
Better access to new medicines stands out as the best fix. In places stuck with only older drugs, clear instructions on dosing, warning signs, and the importance of check-ups keep patients safer. I’ve seen community health workers make a big difference just by helping local residents spot side effects early and communicate with faraway doctors.
Niclofolan’s side effects stand as a reminder that old medicines still serve a purpose where modern options run short, but safety deserves top billing every single time. Doctors, nurses, and patients all play a part in keeping watch, speaking up, and moving toward safer, more effective solutions.
Niclofolan isn’t one of those over-the-counter meds you grab at the drugstore. This medicine serves as an antiparasitic, often handed out to folks dealing with tapeworm infections. Finding reliable instructions makes a difference. Skipping steps or getting creative with dosing usually leads to more headaches, especially since underdosing can give parasites a chance to stick around, and overdosing brings its own issues.
The prescription should match both your weight and the type of infection. Doctors count on body weight for dosing because using a “one size fits all” approach risks not clearing the infection. The usual path looks simple: take Niclofolan as a single dose on an empty stomach, ideally after a short period without eating. Swallow the tablet with water, don’t chew it, and avoid food until at least a few hours pass.
Missing these steps can mess with how much of the medicine actually gets into your system. Food slows down its absorption, and this effect has been shown in studies comparing patients eating versus those who fasted. The whole process relies on those small details.
People often underestimate the danger in guessing or splitting pills their own way. The World Health Organization and researchers from several medical journals talk about the risk of drug resistance when dosing goes wrong. Parasites exposed to inconsistent levels of medicine sometimes survive and adapt. That’s how you end up with treatments that fail in the future—not just for you, but for everyone.
Plus, side effects tend to be mild if you take Niclofolan the way it’s meant to be taken. Nausea and stomach upset happen more when people eat too soon or mess with the timing. Taking Niclofolan with fatty foods can increase absorption in a way that raises the risk of stronger side effects, according to clinical studies.
Sticking to a medical plan always worked out better for me when tackling anything prescription-based. Years back, while helping my uncle manage a similar drug for a parasitic infection, skipping a step meant another appointment, more tests, and extra stress. It’s tempting to look for shortcuts, especially online, but skipping medical supervision has never led to better outcomes in any story I’ve seen or experienced.
Niclofolan doesn’t mix well with a “read the label quickly and move on” approach. Keep the lines open with your health provider; ask for clear, repeated instructions. Write them down if you need to, and follow up if anything feels unclear. Pharmacists spot dosing mistakes all the time and can catch errors before they happen. Using a pill box or setting reminders helps people remember the right moment to take medicine, especially if dealing with kids or older family members.
Also, the rise of counterfeit drugs online means double-checking the pharmacy source matters just as much as the dosing instructions themselves. Reliable, regulated pharmacies reduce risks nobody wants.
Niclofolan plays a vital role for people dealing with tough infections, but the best results always come from listening closely to professionals and respecting the details—not searching for workarounds or guessing at home. Taking charge of your health often means following instructions to the letter, not just to feel better personally but to protect others as well.
Many people learn about new medications during pregnancy through an internet search or a tense chat with their doctor. Niclofolan doesn’t show up often in medical headlines, but when it does, the questions rise fast: safe or not safe for pregnant or nursing individuals? It’s not a minor decision. The answers ripple across the mother’s body, the baby's development, and the comfort (or stress) level of everyone in the family.
Among women I’ve known—friends, family, and clients—the attitude around medication during pregnancy sits somewhere between fierce caution and desperate relief. They want relief from illness, worry about the tiniest risks, and never want to guess about the outcome. Many times, the information they find on a drug like Niclofolan doesn’t match real-life fears.
Doctors often weigh benefits against possible risks. Niclofolan isn’t approved by the FDA for use in pregnancy. No major guideline recommends it as a treatment choice for pregnant or breastfeeding individuals. That’s the reality. For some rare medicines, only animal studies exist, not human ones. In this case, there’s little peer-reviewed data about Niclofolan’s safety in pregnancy. Animal data, where available, shows possible harmful effects on fetal development. No one wants to gamble with that.
The gold standard for medication advice comes from clinical trials. In the case of Niclofolan, there aren’t robust studies published on pregnancy outcomes. Large health organizations like the CDC or ACOG (American College of Obstetricians and Gynecologists) haven’t included it in their safe-use guides. The World Health Organization doesn’t endorse its use during pregnancy and lactation either. That leaves patients and doctors navigating a sea of uncertainties.
Doctors typically steer patients away from any unproven medication if safer alternatives exist. Questions about Niclofolan often circle back to, “Is there an established option that works?” Most of the time, other drugs with long safety histories get the nod. Pharmacists, obstetricians, and primary care doctors usually remind patients that absence of evidence never means evidence of absence. Just because few studies exist on Niclofolan doesn’t make it safe.
Personal stories float around online—one woman saying she took a similar drug and her child grew up just fine, another warning about a vague scare. But anecdotes don’t replace medical science. An experienced doctor would rarely rely on “it’s probably okay” for any critical health question, especially during pregnancy or while breastfeeding. Safety comes first, and uncertainty doesn’t fit well into that equation.
Doctors and patients deserve more data on new and lesser-known medications like Niclofolan. Funding pregnancy-specific clinical trials, especially post-marketing surveillance, could answer these questions better in the future. In the meantime, clear discussions and shared decision-making at the doctor’s office help deal with the gaps in research. Most of all, expecting mothers want honesty and reassurance based on real evidence, not vague possibilities.
If questions about Niclofolan come up, the best approach often means focusing on proven medications, honest conversations about what is known and unknown, and looking for advice from trusted medical professionals who stay updated with the latest research. Until better studies show real answers, most would agree it’s better to be cautious than sorry.
Drug interactions often slip under the radar, but they can turn an effective treatment into a risky gamble. I’ve seen people put full faith in prescriptions, never thinking about what happens when more than one medicine ends up in the daily pill organizer. Ignoring drug interactions can boost side effects, blunt results, or even set off emergencies. So, any new medication, including Niclofolan, calls for a closer look at how it might cross paths with existing prescriptions.
Niclofolan isn’t a household name, though it’s been prescribed in specific cases—often for treating parasitic infections. With less buzz than mainstream meds, some think it flies beneath the radar of interaction risks. The truth is, it has its own set of quirks. Niclofolan’s chemical makeup means it goes through the liver’s enzyme maze, just like dozens of other drugs. Once a drug enters that maze, the potential for interaction grows.
The liver houses enzymes like CYP3A4 and CYP2D6. Many medications depend on these enzymes for breakdown and removal from the body. If Niclofolan either blocks or boosts these enzymes—even slightly—it can shift levels of other drugs up or down. For example, imagine someone on a steady dose of blood thinners, like warfarin. Even a small nudge from another drug can tilt the balance, making blood too thin or not thin enough. Some antibiotics, antifungals, and seizure medications trigger these same liver enzymes. Layering these with Niclofolan increases the puzzle’s complexity.
Over-the-counter options and supplements add another layer to consider. Saint John’s Wort and grapefruit juice can tinker with liver enzymes, meaning that the everyday choices people make in the kitchen or health aisle could set off surprising changes in drug levels.
Speaking with pharmacists and doctors over the years, one story keeps cropping up: unexpected side effects from drug combinations. I remember someone who was taking an antifungal and started Niclofolan without raising the issue at the pharmacy. Within days, dizziness and stomach upset followed. Turns out, both drugs wanted the same liver pathway, and competition slowed the breakdown of one, cranking levels too high.
Interactions can play out quietly. Instead of fireworks, a medication may simple stop working as well, or build up slowly to dangerous levels in the background. Older adults, who tend to juggle more prescriptions, face an extra layer of risk. Slower metabolism and the sheer number of pills make meetings with a knowledgeable pharmacist essential.
A big part of minimizing risk lies in keeping medication lists up to date. Every doctor and pharmacist needs to know exactly what’s being taken—prescription, over-the-counter, or herbal. Online resources like MedlinePlus and the FDA’s drug safety platform provide up-to-date tables and warning lists, but nothing beats a quick conversation with a trusted healthcare provider.
Having honest conversations about lifestyle habits—like drinking grapefruit juice for breakfast—can also make a difference. Patients who take charge of their information and ask questions empower themselves to spot and avoid unsafe mixes.
Niclofolan, like many medicines, offers real benefits when it fits into the bigger medication picture safely. Good information and open communication mean more predictable outcomes and fewer surprises.
| Names | |
| Preferred IUPAC name | 2,2,4,4-Tetrachloro-1,3-bis(trichloromethyl)-1,3-dihydroisothiazole |
| Other names |
Niclofolane MCN-101 KA-104 Niclofolane hydrochloride |
| Pronunciation | /ˌnɪk.ləˈfoʊ.læn/ |
| Identifiers | |
| CAS Number | 132-27-4 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Niclofolan**: ``` C1=CC(=CC=C1C2=NC3=C(N2)C(=O)NC(=O)N3)Cl ``` This is the SMILES string for Niclofolan, which you can use in JSmol or similar 3D molecular viewers. |
| Beilstein Reference | 2412241 |
| ChEBI | CHEBI:76283 |
| ChEMBL | CHEMBL2105936 |
| ChemSpider | 34208 |
| DrugBank | DB13625 |
| ECHA InfoCard | ECHA InfoCard: 1000058-14-9 |
| EC Number | 2597-85-5 |
| Gmelin Reference | 95860 |
| KEGG | D12618 |
| MeSH | Dichloroacetic Acid |
| PubChem CID | 65610 |
| RTECS number | SL8650000 |
| UNII | UXY47977S3 |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | Toxicity Dashboard (EPA): "DTXSID00882098 |
| Properties | |
| Chemical formula | C10H2Cl4FN3O4 |
| Molar mass | 508.129 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.74 g/cm³ |
| Solubility in water | Insoluble |
| log P | 0.82 |
| Vapor pressure | 2.5 × 10⁻⁸ mmHg |
| Acidity (pKa) | 12.84 |
| Basicity (pKb) | 13.17 |
| Magnetic susceptibility (χ) | Diamagnetic |
| Refractive index (nD) | 1.700 |
| Dipole moment | 2.62 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Niclofolan: 0 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -929.5 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -7117 kJ/mol |
| Pharmacology | |
| ATC code | P02CX03 |
| Hazards | |
| Main hazards | May cause cancer. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | Keep out of the sight and reach of children", "Medicinal product subject to medical prescription |
| Signal word | Danger |
| Hazard statements | H300: Fatal if swallowed. H310: Fatal in contact with skin. H330: Fatal if inhaled. |
| Precautionary statements | P261, P264, P271, P273, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P332+P313, P337+P313, P362+P364, P405, P501 |
| NFPA 704 (fire diamond) | 2-2-0 |
| Flash point | Flash point: 173°C |
| Autoignition temperature | 600°C |
| Lethal dose or concentration | LD50 (rat, oral): 57 mg/kg |
| LD50 (median dose) | LD50: 640 mg/kg (oral, rat) |
| PEL (Permissible) | 0.1 mg/m3 |
| REL (Recommended) | 400 mg |
| Related compounds | |
| Related compounds |
Closantel Rafoxanide Oxyclozanide |
